Showing 1 - 6 results of 6 for search 'Craig L Slingluff', query time: 0.02s Refine Results
  1. 1
    Sex and Age-Based Differences in Immune Responses to a Peptide Vaccine for Melanoma in Two Clinical Trials

    Sex and Age-Based Differences in Immune Responses to a Peptide Vaccine for Melanoma in Two Clinical Trials by Serena M. Vilasi, Craig L. Slingluff

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling

    The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling by Craig L Slingluff, Pankaj Kumar, Max O Meneveau, Kevin T Lynch, Sapna P Patel

    Published 2022-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates

    Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates by Craig L Slingluff, Walter C Olson, Christine A Tran, Arabinda Mandal, Jagathpala Shetty, Mriganka Mandal, Bhupal Ban, Eusebio S Pires, Sara J Adair, Todd W Bauer, John C Herr

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist

    Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist by Craig L Slingluff, Gina R Petroni, Walter C Olson, Kimberly A Chianese-bullock, Donna Deacon, Mark Smolkin, William W Grosh, Max O Meneveau, Kevin T Lynch, Elise P Salerno, Elizabeth Woodson, James W Patterson

    Published 2021-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

    MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma by Mark E Smolkin, Gina R Petroni, Kimberly A Chianese-bullock, Kelly T Smith, Geoffrey Weiss, Nico Buettner, Mark Cobbold, Jeffrey Shabanowitz, Nikole Varhegyi, Elizabeth Gaughan, Victor H Engelhard, Rebecca C Obeng, Kara L Cummings, Angela L Ambakhutwala, Amanda Lulu, Paisley Myers, Keira E Mahoney, Emily H Hall, Kathleen Haden, Donald F Hunt, Craig L Slingluff, Jr

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee

    Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee by Lisa H Butterfield, Howard L Kaufman, Steven A Rosenberg, Simon Turcotte, Robert L Ferris, Craig L Slingluff, David Byrd, Jyothi Sethuraman, Brian Gastman, Michael Lim, Michael T Lotze, Mokenge Malafa, Adekunle Odunsi, Fumito Ito, Genevieve Boland, Pranav Murthy, Adam Berger, Haider Mahdi, Piyush K Agarwal, Stephen Broderick, Peter E Fecci, Yuman Fong, Stephanie L Goff, Matthew M Grabowski, Carol D Morris, Rogerio I Neves, Sara I Pai, Sangeetha Prabhakaran, Ragheed Saoud, Joseph Skitzki, Vernon K Sondak, John B Sunwoo, Cecilia CS Yeung

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: